Grape seed extract for lowering high-normal blood pressure
Official title: Hemodynamic Effects of a Standardized Grape Seed Extract Supplementation: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial
Run by Indena S.p.A · NCT07090876 · Data updated 2026-11-12
This will test whether a standardized grape seed extract can lower systolic blood pressure in adults with high-normal blood pressure who follow a low-sodium Mediterranean diet.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Indena S.p.A Industry-sponsored |
| Locations | 1 site (Bologna, Bo) |
| Status | Recruiting |
| Started | April 10, 2026 |
| Main results expected | January 30, 2027 |
| Study ends | January 30, 2027 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT07090876 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–70 with systolic BP 130–139 mmHg and/or diastolic BP 85–89 mmHg, a 10-year CVD risk <10%, able to follow a low-sodium Mediterranean diet and attend study visits are ideal candidates.
✕Probably not a fit
People taking blood-pressure–affecting drugs or supplements, with unstable chronic conditions, significant liver or kidney disease, pregnant or breastfeeding, or with higher cardiovascular risk are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized, placebo-controlled study compares a standardized grape seed extract supplement to placebo in adults aged 18–70 with high-normal blood pressure who are following a low-sodium Mediterranean diet. The primary outcome is change in systolic blood pressure, with secondary outcomes including diastolic blood pressure, other hemodynamic parameters, and the Perceived Stress Score. Eligible participants must have a 10-year cardiovascular risk below 10% and no unstable chronic conditions or confounding medications. The trial is sponsored by Indena S.p.A and conducted at the Cardiovascular Internal Medicine Unit, IRCCS University Hospital of Bologna.
Why it matters
Potential benefit: If effective, the supplement could offer a non-pharmacological option to modestly lower systolic blood pressure and potentially reduce long-term cardiovascular risk in people with high-normal blood pressure.
How similar studies have gone: Small randomized trials and meta-analyses report modest blood-pressure reductions with grape seed extract, but findings are mixed and larger rigorous trials are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or female subjects aged ≥18 and ≤70 years; * Subjects with high-normal blood pressure levels, defined as SBP 130-139 mmHg and/or DBP 85-89 mmHg (according to ESH criteria); * Subjects with an estimated 10-year CVD risk \<10% (as per the SCORE risk prediction algorithm of the European Society of Cardiology); * Subjects capable of communicating, making themselves understood, and complying with the study requirements; * Subjects who agree to participate in the study and have dated and signed the informed consent form. Exclusion Criteria: * Treatment with direct vasodilator drugs or supplements known to affect blood pressure levels; * Chronic pharmacological treatments for any clinical condition not stabilized for at least 3 months; * Known thyroid, renal, or hepatic dysfunction (including transaminase levels ≥3 times the upper limit of normal \[ULN\]); * Current or past history of alcohol abuse; * Pregnancy or breastfeeding; * Known intolerance or hypersensitivity to the active ingredients of the investigational dietary supplement; * History or clinical evidence of any significant concomitant disease that could compromise subject safety or the ability to complete the study.
Where it's running
-
Cardiovascular Internal Medicine Unit, IRCCS University Hospital of Bologna, Bologna, Italy
Bologna, Bo, Italy Recruiting
Study contacts
- Study coordinator: Giovanna Petrangolini, BD
- Email: giovanna.petrangolini@indena.com
- Phone: +39 02 57496493
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartwatch-based program to improve heart health in adults with overweight and cardiometabolic risk
This project will test whether a smartwatch-led exercise, diet, and coaching program can help adults who are overweight or obese with prehypertension, prediabetes, or borderline high cholesterol improve their cardiovascular health.
-
24-hour wearable blood pressure monitoring comparison
We will test if wearable cuffless and cuff-based devices can reliably measure blood pressure over 24 hours compared with a standard ambulatory cuff monitor in adults with normal or high blood pressure.
-
See if stopping alcohol can lower blood pressure and heart risk in adults who drink and have hypertension
This study tests whether abstaining from alcohol for 8 weeks can improve blood pressure and heart-health markers in adults who regularly drink and have high blood pressure.
-
IsoLG scavenger 2-HOBA for salt sensitivity of blood pressure
This study tests whether the IsoLG scavenger 2-HOBA can reduce salt sensitivity and immune activation in adults with salt-sensitive hypertension.
-
Postpartum Cardiovascular Care After Pregnancy
This study tests whether a postpartum education program can improve blood pressure and early heart‑health markers in women in their third trimester to six months after giving birth in Accra, Ghana.
-
BPCARE: Community health worker support to improve blood pressure and medication use
This trial will test whether community health workers can help adult refugees with high blood pressure take their medicines and keep their blood pressure under control compared with enhanced usual care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.